NEW YORK, Aug. 31, 2017 /PRNewswire/ -- Hepatitis C Therapeutics in Asia-Pacific Markets to 2023 - Presence of Outstanding Direct-Acting Antivirals and Late-Stage Pipeline to Transform the Clinical and Commercial Landscape
Read the full report: https://www.reportlinker.com/p05089263
Recent years have seen a revolution in hepatitis C therapeutic development, and the treatment algorithms have rapidly shifted away from interferon-based therapies and towards interferon-free DAA combination therapies. Compared with the older treatments, DAA combination therapies have a favorable safety profile and excellent tolerability and efficacy, achieving cure rates of over 90%.
The recently approved all-oral interferon-free regimens have brought hepatitis C treatment options to a satisfactory level, and leave little space for any remarkable enhancement in clinical performance. Therefore, competition among drug producers will now focus on finer details such as efficacy and safety in niche patient populations, as well as environmental factors, including campaigns to improve treatment access.
The hepatitis C market is currently dominated by highly efficacious DAAs. Sovaldi (sofosbuvir), Gileadâ€™s pan-genotypic HCV polymerase (NS5B) inhibitor, has been the cornerstone of the market for the last two years in the Asia-Pacific region. This success illustrates the importance of providing a drug with an excellent efficacy profile for the majority of patient groups simultaneously.
Asia-Pacific is expected to grow at a compound annual growth rate (CAGR) of 6.4% to reach $8 billion plus in 2023. Despite an expected decline in prevalence due to increasing usage of DAAs that can effectively cure the disease, the overall market size is expected to grow due to increase in the treatment-receiving pool, and usage of costlier therapies.
While Japan, China and India are expected to see growth in market size during the forecast period, mainly due to increases in the treatment receiving pool and the usage of costlier DAAs, Australia and South Korea are likely to witness a decline, mainly due to diminishing treatment-receiving pools resulting from high cure rates.
Four pharmaceutical companies are heavily represented in the lucrative APAC DAA market space, namely AbbVie, Bristol-Myers Squibb, Gilead, and Merck and Co. In addition, each of these companies also has at least one novel DAA regimen under development. However, Bristol-Myers Squibb is the only market participant lacking a pan-genotypic drug combination in its pipeline â€" a consequence of its strategy of focusing on the Japanese HCV market.
The hepatitis C Asia-Pacific market will be valued at $8.31 billion in 2023, growing from $5.38 billion in 2016 at a CAGR of 6.4%.
- How will pan-genotypic therapies such as glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir contribute to growth?
- What effect will the patent expiration of branded therapies have on market value?
The hepatitis C pipeline contains a range of molecule types and molecular targets, including those that are well established in hepatitis C, and novel target therapies.
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline therapies fulfill the unmet needs of the hepatitis C market?
- What implications will the increased focus on pan-genotypic therapies have on the future of hepatitis C treatment?
Late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- How will the approval of glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir, which hold a key advantage in terms of reducing the treatment duration, affect the competitive landscape, with no therapy currently available to address this unmet need?
The market forecasts indicate that China and Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
- What will be the impact of available therapies with high cure rates on prevalence?
- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
- Which countries are in the best situation currently for the eradication of HCV?
Various drivers and barriers will influence the hepatitis C market over the forecast period.
- What are the barriers that will limit the uptake of available and upcoming therapies in the assessed countries?
- Which factors are most likely to drive the market in these countries?
Licensing deals are the most common form of strategic alliance in hepatitis C, with total deal values ranging from under $10m to over $1.5 billion.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?
Reasons to buy
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the hepatitis C market in terms of dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the hepatitis C pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict hepatitis C market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the hepatitis C deals landscape by analyzing trends in licensing and co-development deals.
Read the full report: https://www.reportlinker.com/p05089263
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/hepatitis-c-therapeutics-in-asia-pacific-markets-to-2023---presence-of-outstanding-direct-acting-antivirals-and-late-stage-pipeline-to-transform-the-clinical-and-commercial-landscape-300512589.html